Malaria during pregnancy: New study assesses risks during first trimester
December 13, 2011 in Obstetrics & gynaecologyThe largest ever study to assess the effects of malaria and its treatment in the first trimester of pregnancy has shown that the disease significantly increases the risk of miscarriage, but that treating with antimalarial drugs is relatively safe and reduces this risk.
In the study, carried out at the Shoklo Malaria Research Unit (SMRU), in Thailand and funded by the Wellcome Trust, researchers examined medical records of women attending the unit's antenatal clinic over the 25 years since it was founded.
Malaria kills around one million people each year, mainly children and pregnant women. Malaria in pregnancy is a major cause of maternal mortality, and low birth weight which predisposes to neonatal mortality. The disease is caused by infection with the malaria parasite, with two major species Plasmodium falciparum and Plasmodium vivax commonly infecting pregnant women in the South East Asia region The parasites are transmitted into the blood stream through the bite of infected mosquitos. They proceed to enter the liver where they multiply before leaving and infecting red blood cells. P. vivax is able to re-emerge from the liver stage which cannot be treated in pregnancy.
The most effective drug for treating malaria is artemisinin, which is usually given as part of a combination therapy, a cocktail of drugs aimed at treating the disease whilst reducing the risk of the emergence of parasites resistant to one particular drug. Artemisinin combination therapies (ACT) are recommended by the World Health Organization for the treatment of malaria except in the first trimester. This is because animal studies have indicated that the drugs can be toxic to embryos.
Despite the risks to pregnant women, there is very little published evidence on the effects of malaria and antimalarial drug exposure during the first trimester of pregnancy. This is in part because antenatal clinic services are often unavailable in the rural tropics and if they are, women rarely attend the clinics before their second trimester. Also, pregnant women are usually excluded from clinical trials of new drugs because of the risks of adverse effects; no randomised controlled trial has ever been carried out on how best to treat malaria in the first trimester.
In a study published today in the journal Lancet Infectious Diseases, researchers at the SMRU, part of the Wellcome Trust-Mahidol University-Oxford University Tropical Medicine Research Programme, examined the records of all women attending antenatal clinics at the unit. Of these, 16,668 had no malaria during pregnancy, whilst 945 had only a single episode during their first trimester and no episodes later in pregnancy.
Around one in five pregnancies resulted in miscarriage when malaria was not a factor. Symptomatic malaria increased the risk of miscarriage to one in two pregnancies; for asymptomatic malaria, the risk of miscarriage was one in three pregnancies. In women with malaria, more severe disease, higher levels of parasites in the blood and infection at an earlier stage of pregnancy increased the risk of miscarriage further. The risks associated with miscarriage were similar for P. falciparum and P. vivax infections.
P. falciparum infections were treated with quinine or artesunate, or inadvertently with ACT, and P. vivax with chloroquine. Of the women treated (irrespective of symptoms), 26% miscarried following chloroquine, 27% following quinine and 31% following artesunate. After inadvertent treatment with an ACT the miscarriage rate was 24%, comparable to the rate associated with other treatments.
"Malaria is a potentially deadly disease and is particularly dangerous during pregnancy, both to the health of the mother and to the health of her unborn child," explains Dr Rose McGready from the Shoklo Malaria Research Unit. "Understanding the risks is essential for weighing up the treatment options. Our work has highlighted the particular risk factors with malaria infection during pregnancy. Particularly worrying is the risk of miscarriage even when the disease is asymptomatic. However, whilst the dangers of miscarriage are considerable, our study offers some good news, that the most common drugs reduce this risk significantly."
Combating infectious diseases is one the strategic priorities of the Wellcome Trust. Much of this work is carried out at a local level in regions where disease is endemic. This includes several major overseas programmes, including the Wellcome Trust-Mahidol University-Oxford University Tropical Medicine Research Programme.
Dr Jimmy Whitworth, Head of International Activities at the Wellcome Trust, says: "This is a very important observational study on the risks of treating malaria in women in early pregnancy, a key high-risk group for this infection. These results, which come from the research group that has done the majority of studies of malaria in pregnancy anywhere in the world, show that antimalarial treatment with standard first-line drugs reduces the risk of miscarriage in the first trimester. These findings are likely to change practice guidelines worldwide and to save the lives of many women and unborn children."
Journal reference:
Lancet Infectious Diseases
Provided by
Wellcome Trust
-
Better treatments for malaria in pregnancy are needed
Jun 17, 2008 |
not rated yet |
0
-
Most effective malaria drug regimens highlighted in study
Sep 09, 2010 |
not rated yet |
0
-
Profiling malaria-causing parasites
Feb 07, 2011 |
not rated yet |
0
-
New study finds 125 million pregnancies globally at risk from malaria every year
Jan 26, 2010 |
not rated yet |
0
-
Studies identify more effective treatment for malaria control during pregnancy in Africa
Jun 20, 2007 |
not rated yet |
0
-
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
May 25, 2012 |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (4) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Force in a magnetic coupling
9 hours ago
-
Sign of scalar product in electric potential integral?
16 hours ago
-
Heat engines: how can we yield work?
17 hours ago
-
Work done by us on the spring
May 25, 2012
-
Surface current density
May 25, 2012
-
Work done on body moving in a circle
May 25, 2012
- More from Physics Forums - Classical Physics
More news stories
Phone contact with nurses linked with better outcomes for women with gestational diabetes
Among women with gestational diabetes mellitus, referral to a telephone-based nurse management program was associated with lower risk of high baby birth weight and increased postpartum glucose testing, according to Kaiser ...
Obstetrics & gynaecology
May 25, 2012 |
not rated yet |
0
Progestin treatment for polycystic ovarian syndrome may reduce pregnancy chances
(Medical Xpress) -- The hormone progestin, often given as a first step in infertility treatment for polycystic ovary syndrome (PCOS), appears to decrease the odds of conception and of giving birth, according to a study by ...
Obstetrics & gynaecology
May 25, 2012 |
not rated yet |
0
|
Women trying to have babies face different clock problem
A new Northwestern University study shows that the biological clock is not the only clock women trying to conceive should consider. The circadian clock needs attention, too.
Obstetrics & gynaecology
May 23, 2012 |
not rated yet |
0
|
UK may allow IVF for older women, same-sex couples
(AP) -- A powerful health advisory agency says Britain should extend free fertility treatments to women up to age 42 as well as same-sex couples, recommendations likely to be followed by many of the U.K.'s medical centers.
Obstetrics & gynaecology
May 22, 2012 |
not rated yet |
0
The Women's Health Initiative study and hormone therapy -- what have we learned 10 years on?
In July 2002 the publication of the first Women's Health Initiative (WHI) report caused a dramatic drop in Menopausal Hormone Therapy (HT ) use throughout the world. Now a major reappraisal by international experts, published ...
Obstetrics & gynaecology
May 22, 2012 |
not rated yet |
0
Travel to high altitudes tied to Crohn's, colitis flare-ups
(HealthDay) -- People with inflammatory bowel disease, which includes Crohn's disease and colitis, may be at increased risk for flare-ups when they fly or travel to high altitudes for skiing or mountain climbing, ...
Family history of Alzheimer's affects functional connectivity
(HealthDay) -- Cognitively normal individuals with a family history of late-onset Alzheimer's disease (AD) may display lower resting state functional connectivity in the default mode network (DMN) of the brain, ...
Transvaginal mesh op restores pelvic organ prolapse at price
(HealthDay) -- Transvaginal mesh (TVM) procedures are effective for anatomical restoration of pelvic organ prolapse (POP), but patients report a worsening of sexual function following surgery, according to ...
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...
Weight struggles? Blame new neurons in your hypothalamus
New nerve cells formed in a select part of the brain could hold considerable sway over how much you eat and consequently weigh, new animal research by Johns Hopkins scientists suggests in a study published in the May issue ...
Thioridazine kills cancer stem cells in human while avoiding toxic side-effects of conventional cancer treatments
A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments.